Search Result

Results for "

CDK9-IN-1

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (6) Bcl-2 Family (1) CDK (25) EGFR (1) FLT3 (1) HIV (1) Ligands for Target Protein for PROTAC (3) PROTACs (3) Reactive Oxygen Species (1)
By Research Areas:	Cancer (26) Infection (1) Inflammation/Immunology (1)

Targets Recommended: AIM2 NEKs

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-13231

*CDK9-IN-1* 2 Publications Verification	CDK HIV	Infection
CDK9-IN-1 is a novel, selective *CDK9* inhibitor for the treatment of HIV infection, with an IC₅₀ of 39 nM for CDK9/CycT1, extracted from reference, compound 87.

HY-147026

CDK9-IN-15	CDK	Cancer
CDK9-IN-15 (compound 50) is a potent *CDK9* inhibitor .

HY-130852

CDK9-IN-11	CDK Ligands for Target Protein for PROTAC	Cancer
CDK9-IN-11 is a potent *CDK9* inhibitor. CDK9-IN-11 is the ligand for the PROTAC CDK9 Degrader-1 (HY-103628) .

HY-12871C

Atuveciclib S-Enantiomer BAY-1143572 S-Enantiomer	CDK	Cancer
Atuveciclib S-Enantiomer (BAY-1143572 S-Enantiomer) is a potent and selective *CDK9* inhibitor, which inhibits *CDK9/CycT1* with an IC₅₀ of 16 nM.

HY-12871

Atuveciclib Racemate 1 Publications Verification BAY-1143572 Racemate	CDK	Cancer
Atuveciclib Racemate (BAY-1143572 Racemate) is the racemate mixture of Atuveciclib. Atuveciclib is a potent and highly selective, oral *P-TEFb/CDK9* inhibitor which supresses *CDK9/CycT1* with an IC₅₀ of 13 nM.

HY-12871B

Atuveciclib 5+ Cited Publications BAY-1143572	CDK	Cancer
Atuveciclib (BAY-1143572) is a potent and highly selective, oral *PTEFb/CDK9* inhibitor. Atuveciclib (BAY-1143572) inhibits *CDK9/CycT1* with an IC₅₀ of 13 nM .

HY-147796

EGFR/HER2/CDK9-IN-1	EGFR CDK	Cancer
EGFR/HER2/CDK9-IN-1 (Compound 4) is a potent inhibitor of EGFR/HER2/CDK9 with IC₅₀*s of 90.17, 131.39, and 67.04 nM, respectively. EGFR/HER2/CDK9-IN-1* exhibits remarkable antitumor activity .**

HY-156083

CDK9-IN-28	CDK	Cancer
PROTAC CDK9/CycT1 Degrader-1 (compounds 10) is a potent inhibitor of *CDK9. PROTAC CDK9/CycT1* Degrader-1 can be used as a PROTAC target protein ligand for PROTAC synthesis. PROTAC CDK9/CycT1 Degrader-1 shows strong anti-proliferative activity in solid tumors .

HY-156795

*PROTAC CDK9/CycT1* Degrader-2**	CDK	Cancer
PROTAC CDK9/CycT1 Degrader-2 is a inhibitor of *CDK9, with the IC₅₀* of 45 nM .

HY-111356

IIIM-290	CDK	Cancer
IIIM-290 is a potent and oral CDK inhibitor with IC₅₀s of 90 and 94 nM for CDK2/A and CDK9/T1.

HY-12871A

(+)-Atuveciclib (+)-BAY-1143572	CDK	Cancer
(+)-Atuveciclib is the isomer of Atuveciclib (Racemate) (HY-12871). Atuveciclib Racemate (BAY-1143572 Racemate) is the racemate mixture of Atuveciclib. Atuveciclib is a potent and highly selective，oral *P-TEFb/CDK9* inhibitor which supresses *CDK9/CycT1* with an IC₅₀ of 13 nM.

HY-148521

PROTAC FLT3/CDK9 degrader-1	CDK FLT3 PROTACs Apoptosis	Cancer
PROTAC FLT3/CDK9 degrader-1 is a potent FLT3 and *CDK9* dual PROTAC degrader. PROTAC FLT3/CDK9 degrader-1 induces apoptosis and effective degradation of target proteins FLT3 and CDK9. PROTAC FLT3/CDK9 degrader-1 has the potential for the research of FLT3-ITD mutated AML .

HY-157980

CDK9-IN-32	CDK	Cancer
CDK9-IN-32 (compound 006-3) is a *CDK9* inhibitor .

HY-115729

PROTAC CDK9 ligand-1	Ligands for Target Protein for PROTAC	Cancer
PROTAC CDK9 ligand-1 is a *CDK9* ligand that can be used in the synthesis of PROTACs.

HY-153260

TP-1287	CDK	Cancer
TP-1287, a prodrug of Alvocidib (HY-10005), is an orally active *CDK9* inhibitor .

HY-103628

PROTAC CDK9 Degrader-1 1 Publications Verification	PROTACs CDK	Cancer
PROTAC CDK9 Degrader-1 is a PROTAC connected by ligands for Cereblon and CDK as a selective *CDK9* degrader.

HY-16559A

Riviciclib P276-00 free base	CDK	Cancer
Riviciclib (P276-00 free base) is a potent cyclin-dependent kinase (CDK) inhibitor, which inhibits *CDK9-cyclinT1, CDK4-cyclin D1, and CDK1-cyclinB* with IC₅₀s of 20 nM, 63 nM, and 79 nM, respectively . Riviciclib shows antitumor activity on cisplatin-resistant cells .

HY-16559

Riviciclib hydrochloride 3 Publications Verification P276-00	CDK Apoptosis	Cancer
Riviciclib hydrochloride (P276-00) is a potent cyclin-dependent kinase (CDK) inhibitor, which inhibits *CDK9-cyclinT1, CDK4-cyclin D1, and CDK1-cyclinB* with IC₅₀s of 20 nM, 63 nM, and 79 nM, respectively . Riviciclib hydrochloride (P276-00) shows antitumor activity on cisplatin-resistant cells .

HY-10492

Dinaciclib Maximum Cited Publications 41 Publications Verification SCH 727965	CDK Apoptosis	Cancer
Dinaciclib (SCH 727965) is a potent inhibitor of CDK, with IC₅₀s of 1 nM, 1 nM, 3 nM, and 4 nM for CDK2, CDK5, CDK1, and *CDK9*, respectively .

HY-115729A

(R)-PROTAC CDK9 ligand-1	Ligands for Target Protein for PROTAC CDK	Cancer
(R)-PROTAC CDK9 ligand-1 (Compound 19.4) is a *CDK9*-targeting degrader that can be used to synthesize PROTAC with antitumor activity .

HY-155065

SB-1295	Reactive Oxygen Species Apoptosis CDK	Cancer
SB-1295 is an orally active *CDK9/T1* inhibitor (IC₅₀=0.17 μM). SB-1295 shows antiproliferative activity in HCT 116 and MIA PaCa-2 cells. SB-1295 also induces MIA PaCa-2 cell death by inducing intracellular ROS production, reducing mitochondrial membrane potential and inducing apoptosis. SB-1295 has the potential to study cancer .

HY-101212

Fadraciclib 5 Publications Verification CYC065	CDK	Cancer
Fadraciclib (CYC065) is a second-generation, orally available ATP-competitive inhibitor of *CDK2/CDK9** kinases* with IC₅₀s of 5 and 26 nM, respectively .

HY-153221

QR-6401	CDK	Cancer
QR-6401 is an orally active and selective macrocyclic CDK2 inhibitor with IC₅₀ values of 0.37, 10, 22, 34 and 45 nM for CDK2/E1, *CDK9/T1, CDK1/A2, CDK6/D3* and CDK4/D1, respectively. QR-6401 has potent antitumor activity in an OVCAR3 ovarian cancer xenograft model. QR-6401 has the potential to be used in the study of cancer .

HY-131063

CDK6/9-IN-1	CDK	Cancer
CDK6/9-IN-1 (compound 66) is an orally active active and dual CDK 6 and CDK 9 inhibitor, with IC₅₀ values of 40.5 nM and 39.5 nM for CDK6 anmd CDK9, respectively .

HY-123034

CDKI-83	CDK Bcl-2 Family Apoptosis	Cancer
CDKI-83 is a potent *CDK9* and CDK1 inhibitor with K_i values of 21 nM and 72 nM for CDK9/T1 and CDK1/B, respectively. CDKI-83 demonstrates effective anti-proliferative activity in human tumour cell lines with a GI₅₀<1 μM. CDKI-83 effectively induces apoptosis in A2780 human ovarian cancer cells. CDKI-83 reduces phosphorylation at Ser-2 of RNA polymerase II (RNAPII) by inhibiting cellular CDK9 activity, and down-regulates Mcl-1 and Bcl-2. CDKI-83 has the potential for anti-cancer research .

HY-12445

Asnuciclib 2 Publications Verification CDKI-73; LS-007	CDK Apoptosis	Inflammation/Immunology Cancer
Asnuciclib (CDKI-73; LS-007) is an orally active and highly efficacious *CDK9* inhibitor, with K_i values of 4 nM, 4 nM and 3 nM for CDK9, CDK1 and CDK2, respectively. Asnuciclib down-regulates the RNAPII phosphorylation. Asnuciclib is also a novel pharmacological inhibitor of Rab11 cargo delivery and innate immune secretion .

HY-148065

FMF-06-098-1	PROTACs	Cancer
FMF-06-098-1 is a multitargeted depressant. FMF-06-098-1 can be used to target degradation kinases which degrades AAK1, AΒL2, AURKA, AURKB, BUBIB, CDC7, CDK1, CDK12, CDK13, CDK2, CDK4, CDk6, CDK7, CDK9, CHEK1, CSNKID, EPHA1, PER, FGFR1, GAK, IRAK4, ITK, LIMK2, MAP4K2, MAP4K3, MAPK6, MAPK7, MARK4, MELK, PKN3, PLK4, PRKAA1, PTK2, PTK6, RPS6KA4, S1K2, STK35, TNK2, UHMK1, ULK1, and WEE1 .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.

CDK9-IN-1

Inhibitors & Agonists